The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023(Supplement) Cellular Brain Repair for Parkinson’s Disease: Preclinical Therapeutic Validation of Biomaterial-supported Cell Transplants Coupled with Immunosuppression
Study Rationale: Although transplantation of stem cell-derived brain cells is a promising therapeutic approach for Parkinson’s disease (PD), only a small fraction of the cells that are transplanted...
-
Data-Driven Subtyping and Stratification Program, 2023Identifying Distinct Patterns in Parkinson’s Disease Progression Using Integrative, Data-driven Subtype Analysis
Study Rationale: Parkinson’s disease (PD) is associated with diverse motor and non-motor manifestation that progress gradually over time. Although this progression differs from individual to...
-
Research Grant, 2023(Supplement) PET Imaging Probe Development for Alpha-synuclein
Study Rationale: Alpha-synuclein is a protein that can clump to form Lewy bodies and lewy neurites, which are a hallmark of Parkinson's disease. Being able to identify these clumps in living patients...
-
Research Grant, 2023Leveraging Gene Expression Data to Redefine Parkinson’s Disease and the Pathways Driving Disease in Different Individuals
Study Rationale: People with Parkinson’s disease (PD) share some common problems, such as stiffness, slowness of movement and tremors. However, these symptoms vary in severity, and individuals often...
-
Parkinson’s Pathway Molecular Data Analysis Program, 2023Characterization of Parkinson’s Disease Clinical Subtypes Using Multiple Immunologic and Genetic Markers
Study Rationale: Parkinson’s disease (PD) is an umbrella term that encompasses a highly heterogeneous domain of clinical manifestations, which makes the development of effective therapeutic strategies...
-
Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2023(Supplement) Testing the Neuroprotective Efficacy of Modulating the Lysosomal Gene Atp6v0a1
Study Rationale: The lysosome is a part of a cell involved in degrading and recycling proteins and other large molecules. Parkinson's disease (PD) is linked to lysosomal dysfunction. In this study, we...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.